Physicians play an integral role in pharmaceutical development. And in an effort to support residents who have an interest in drug and product development, the American Academy of Dermatology (AAD), in partnership with Galderma Research & Development, has launched the American Academy of Dermatology Translational Biotechnology Fellowship. The new fellowship will offer dermatologists the opportunity to work in drug development and translational medical research at Galderma's R&D facility located in Sophia Antipolis, France. The company will host two one-year fellowships, one beginning in fall 2013 and one beginning in fall 2014. This learning opportunity was developed to allow the physician to advance science and explore career options within a pharmaceutical industry setting.
According to the AAD, the fellow will gain knowledge of the specific requirements of drug development and be given opportunities for creative exploration within the pharmaceutical industry environment. The AAD will provide the selected candidates a stipend to cover their costs during the terms of the fellowships. Galderma will host and provide necessary resources to support and mentor the Fellows.
Preference will be given to candidates who are in their last year of residency in an accredited American College of Graduate Medical Education dermatology residency program. Candidates must be physician members of the AAD who have satisfactorily completed their residencies no more than three years before the planned start date. Candidates must be interested in pursuing research and exploring careers in an industry setting. The AAD will review fellowship applications and recommend one candidate each year the fellowship is offered.
The application for the fall 2013 fellowship is available at www.aad.org/biotechfellowship . Submissions will be accepted through May 31, 2013. The 2013 recipient will be notified in July 2013. The application for the fall 2014 fellowship will be available on the website in mid-June 2013. The 2014 recipient will be notified in December 2013.
“This fellowship represents a new level of cooperation between the American Academy of Dermatology and industry to advance the needs of the specialty. This is a unique opportunity for a recent dermatology residency graduate and AAD member to participate in the development of innovative medical solutions," said Dirk M. Elston , MD, FAAD, board-certified dermatologist and president of the American Academy of Dermatology.
“Galderma is a global leader in dermatology and a long-time partner of the AAD. This unique fellowship is a tangible example of Galderma's real commitment to supporting dermatologic research and young physicians' medical education,” said François Fournier, president of Galderma for North America. “Galderma is exclusively focused on dermatology and invests approximately 20% of its revenues each year to discover and develop new products and accessing innovative technologies.”